Post Time: 2025-02-18
Error: No content files found.What’s new with type 2 diabetes care in 2021 When and how are SGLT2 inhibitors and GLP1 agonists used? Dr Ryan Paul is an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD) and recently led the development of the NZSSD guidance on the management of type 2 diabetes in New Zealand. Dr Paul is heavily involved in teaching primary care clinicians, diabetes nurse prescribers and endocrinology trainees. THE TOPIC WILL INCLUDE: • The updated treatment algorithm of type 2 diabetes in New Zealand • When and how to use SGLT2 inhibitors and GLP1 receptor agonists • Who does and who Read Significantly more does not Suggested Resource site meet the special authority criteria for funded SGLT2 inhibitors and GLP1 receptor agonists • New recommendations for the screening and management of type 2 diabetes in Aotearoa New Zealand • Achieving equity in diabetes outcomes in Aotearoa New check out this site Zealand • Case discussion